Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07733817
NA

Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

Sponsor: Centre Francois Baclesse

View on ClinicalTrials.gov

Summary

The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX regimen in adjuvant treatment, assessed using the oxaliplatin-specific scale of Levi.

Official title: Impact of Probiotic Supplementation on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer: a Phase III Randomized Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

130

Start Date

2026-10-01

Completion Date

2036-04-01

Last Updated

2026-07-30

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

PROBIOTIC SUPPLEMENTATION BY OXXYSLAB®

PROBIOTIC treatment (OXXYSLAB®) starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.

DIETARY_SUPPLEMENT

PLACEBO supplementation

PLACEBO supplementation starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.

Locations (7)

Centre François Baclesse

Caen, Centre François Baclesse, France

Ch Aunay-Bayeux

Bayeux, France

CHU

Caen, France

Centre Oscar Lambret

Lille, France

CHU

Lille, France

CHU

Rouen, France

CH

Saint-Lô, France